🔗 Share this article

Elected officials have expressed alarm that the United Kingdom's recent agreements with the US administration are "lacking a solid foundation." This follows revelations that a recently announced deal on pharmaceutical tariffs, which promises zero tariffs in exchange for the NHS facing higher prices, lacks any underlying contract beyond broad headline terms published in government press releases.

Lacking Legal Footing

The US-UK pharmaceuticals agreement, promoted as a "landmark" achievement, remains an "statement of intent" without a signed legal text. It has been highlighted that the public statements from the UK and US governments describe the deal in divergent terms. The British version celebrates securing "zero per cent tariffs" as a unique achievement, while the American announcement highlights the agreement for the NHS to pay significantly more for new medications.

"The danger exists that the UK government has made commitments to raise drug prices in return for little more than a verbal promise from President Trump," said David Henig, a trade expert. "It is documented he has a tendency for not honouring his word."

Wider Concerns Amidst a Suspended Agreement

Worries have been amplified by Washington's move to pause the high-value digital accord, which was previously called "a huge leap forward" in the bilateral relationship. The US cited a insufficient movement from the UK on lowering trade barriers as the reason for the pause.

Additionally, concessions promised for British farmers as part of an earlier tariff deal have not been formally signed off by the US, despite a imminent January deadline. "Our understanding is that the US has not yet signed off the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

In confidential discussions, ministers have expressed concerns that the government's US-UK accords are unstable and unpredictable. One minister described the series of agreements as "built on sand," while another framed the situation as the "current reality" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, chair of the health select committee, remarked: "The only thing more surprising than Trump's temper tantrums is the UK government's credulous faith that his administration is a reliable partner. The NHS is not a bargaining chip."

Government Downplays Risks, Points to Gains

Ministry sources have sought to reduce the possibility of the US backing out of the pharmaceuticals deal. One source indicated the US pharmaceutical industry itself had been pushing for the agreement, wanting clarity on imports and pricing, making it less abstract than the paused tech deal.

Officials concede that volatility is a feature of dealing with the Trump administration. However, they contend that the UK has secured concrete outcomes for businesses, such as lower steel tariffs compared to other nations. "Our achievement of 25% steel tariffs, which is more favorable than the rate for the rest of the world, is not flimsy," one official said.

However, issues have emerged in carrying out the initial US-UK accord. Promised access for British beef have failed to be approved, and the commitment to "eliminate duties on UK metals" has is still pending, with tariffs staying at 25%.

Looking ahead, the two sides have scheduled to restart talks on the paused tech prosperity deal in January, following what were described as "very positive" meetings between UK and US officials in Washington.